Member Info for Quickdraw18

Appreciate the thumbs up try2buy low. I don't know specifics of a Lighthouse lab kit out. It definitely wouldn't involve the use of q's.
From recall the Cambridge, AstraZeneca lab utilised some tailored manufacturing equipment to enable COVID HT-Direct test and which removed the RNA extraction process

So if HT-Direct were to be adopted by a second Lighthouse Lab this production change would be required. I'd imagine a revision to an existing lab over creation of a new one.

The planned Lemington Spar lab would make sense to adopt HT-Direct as its in the process of being brought on line.

SNPsig is a second stage test, which is run against all postive tests to screen for know variants with flagged postive tests with unknown genetic makers then being sent for sequencing which is mostly undertaken by Oxford Nanopore. I'm not sure if SNPsig is compatible with the high-throughput configuration of the Cambridge Lighthouse

In respect of the PerkinElmer comments they were taken from their Q4 Earnings call 02/02.

https://seekingalpha.com/article/4402947-perkinelmer-inc-pki-ceo-prahlad-singh-on-q4-2020-results-earnings-call-transcript

Big things are happening within the UK diagnostics landscape. That lighthouse needs a bigger bulb, oh we added one last week. We're out shining the other lighthouses, job done

It's the tool who's been bashing Nova and PCR Martin Van Buren lol

Wilson you can get a half point, Boros was the 3rd person not Martin Van Buren followed on Twitter.

Martin Van Buren of the "The Phoenix Fund" which focuses on distressed debt returned -17.5% over 12 months. The top fund in the same category returned 28.2% over 12 months.

The Phoenix Fund costs 2% per annum

Answers been tweeted. And the award for prime plonkers goes to....... Hahaha

https://twitter.com/NewFormsResearc/status/1366426501223231492?s=19

I'll be posting the answer on twitter at 4:30

If you've got it congratulations, if you haven't shame on you. You should improve your researching if you are to be an investor lol

He deserves a face palm emoji. I'll be serving one on twitter in a bit

Nice guess Wilson, it's way more obvious answer lol

"Numbers of tests performed still growing significantly and not showing any sign of slowing down soon, especially with winter flu season coming. Even after a vaccin comes to the market, testing will be crucial for some time. Competition will grow, but plenty of space. #EKF #NCYT"

Who wants to play game of who's tweets this anyway?

"late to buy into Novacyt, but have spent the whole day yesterday researching them. Very impressive what they have built in less than a year. Current valuation just implies a relatively small premium to the expected net cash flow of all orders received"

6th October 2020

Tay spotted the same wording in 2020 outlook, issues 28th feb. 3 days before they launched PCR test
"In February '20 he gave a similar 'warning' about not being able to predict earnings.

Went on to make nearly £300 mill with barely any cash to hand.

2021 and he's got x10 the amount of cash to work with over 2020"

https://twitter.com/TaylorQuant/status/1363813940577378309?s=19

#Novacyt path to success
2020:
31/01 - PCR test launched
07/02 - 1st orders
17/02 - One of ?? 1st CE-Marked ??
27/02 - £0.93m rev
30/03 - £17.8m rev
08/04 - WHO ??
13/07 - £63.3m 1st h rev
16/11 - PROmate™

2021:
29/01 - £213.7m 2nd h rev, £277m FY
02/02 - SNPsig® variant launch

18/06 - Launch Exsig direct
15/10 - IT-IS takeover
29/09 - DHSC contract
3 months
16/11 - ProMATE

Appreciate your advice Porky and sharing your past experience. Sadness me to see little more investors getting stitched up. Our sentient has been hurt in the short term by LFTs and has caused discourse within the confused government. These are but short term issues IMO.
I'll make no promises in respect to Avacta BB, but I have been working on a more efficient means of communicating with the mass public, am just playing around by here. Have a few updates to make to my research and await Boris's Road map. Will then see which of the national papers that have previously shone lights on issues with LFTs would like to consider my research.
Would be good if Avacta fan boys would take their sovereign thoughts over to that forum as don't see that person posting their aspirations over there. I'm off out for some exercise and will then finish off my piece for hopefully future revealing newspaper article.

True apologies to the sincere Avacta holders, truly mean you well and prosperity

The testing process has suddenly increased about 10-fold; earlier about 500-700 international passengers were being tested per day, the lab is now staring at 7,000 plus numbers.

While the lab infrastructure is equipped to even test above 15,000 samples per day, the operations team comprising data entry operators and sample collection technicians had to be increased 10 folds to handle the large inflow of passengers from the UK, Europe, and the Middle East.

"A massive recruitment drive was launched immediately after the SOP was announced and over 200 staff was recruited overnight and trained over the next two days," Genestrings lab sai

https://www.hindustantimes.com/india-news/testing-increased-at-igi-airport-to-help-detect-new-covid-19-variant-101613978962677.html

tyche100 could you give me one example please?

I do apologise for my typing

Sorry no one can make me do anything. Free speech and I'll. If you can deal with my insights I'd suggest you close your eyes

Bought £36,321.98 on 20th April

Sold £56,338 20th July @ £1.30

Tell that to Porton Down Doze. Is no good avacta knowing better than the evaluator

Much like trying to tell an exam invigilator who gave a U that you they are wrong.

Innova, Novacyt, PerkinElmer, Thermo Fisher, Abbott, LumiraDx, Oxford Nanopore all had tests approved and even Sure Screen got a deal.

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/coronavirus-covid-19-serology-and-viral-detection-testing-uk-procurement-overview#products-in-the-pipeline-tvg

PCR based slant

"Feb 4 (Reuters) - Roche will double monthly production of PCR tests to detect active COVID-19 infections to 40 million in the first quarter and roughly 70 million by July, its diagnostics chief said on Thursday.

"We will see still a lot of testing, particularly in the first half of the year," diagnostics chief Thomas Schinecker said on a call. "We'll see how things develop in the second half of the year, currently it's looking likely that testing will remain rather high for the remainder of 2021."

https://www.reuters.com/article/roche-results-testing-idUSFWN2KA0FR

Roche with all their buying power and economies of scale have 50% spare Antigen LFT capacity at end of jan. Do you think Avacta can catch up with them and Abbott and compete on price

"Roche can also make 100 million rapid antigen tests monthly, but is now making only about half that via South Korean partner SD Biosensor, in part because it does not yet sell them in the United States. It can make up to 100 million antibody tests, too, to detect of somebody has had a past coronavirus infection or if they have an immune response to a vaccine, though demand is currently around 10-15 million monthly, Schinecker said. (Reporting by John Miller; Editing by Michael Shields)"

https://www.reuters.com/article/roche-results-testing-idUSFWN2KA0FR

LFT's are a fad, as for the rest of the Avacta
business that's been running since 1999

With no mention of first 13 yrs of failed business model on in Key Investor page or their origination as animal bio company in 1999. Page says they came to AIM in 2006.

I judge companies on their intentions and ability to execute their plans. Summer 2020, wonder what they were saying in 2011 as the SP rose and directors left and in 2017?

Took the hype of LFT's to resuscitate the Share price. Now this bubble has popped.

By the way Roche with all their buying power and economies of scale have 50%,spare Antigen LFT capacity at end of jan. Do you think Avacta can catch up with them and Abbott and compete on price

"Roche can also make 100 million rapid antigen tests monthly, but is now making only about half that via South Korean partner SD Biosensor, in part because it does not yet sell them in the United States. It can make up to 100 million antibody tests, too, to detect of somebody has had a past coronavirus infection or if they have an immune response to a vaccine, though demand is currently around 10-15 million monthly, Schinecker said. (Reporting by John Miller; Editing by Michael Shields)"